Series A8 October 2019

Invizius raises £2.8m in seed funding led by Mercia to advance dialysis treatments.

The funding round was led by Mercia to support pre-clinical testing and manufacturing as the company prepares for clinical trials.

£2.8MSeries A

Invizius is a medical technology company developing anti-inflammatory treatments to mitigate cardiovascular risks for dialysis patients. Its H-Guard product coats medical filters to prevent adverse immune responses.

Invizius has secured £2.8m in seed funding to advance its anti-inflammatory technology designed for dialysis patients. The round was led by Mercia, with participation from Downing Ventures, Old College Capital, and the Scottish Investment Bank. The capital will enable the Edinburgh-based firm to conduct pre-clinical testing, handle manufacturing, and prepare for upcoming clinical trials.

Originating as a spin-out from the University of Edinburgh, the company aims to address the high incidence of cardiovascular complications among long-term dialysis patients. Its proprietary H-Guard product coats filtration equipment to suppress the immune system response that causes chronic inflammation during treatments. The fresh capital supports the enterprise as it targets a subsequent Series A raise within 18 months.

From the founder

Investor perspective

"Invizius is a great example of how Mercia can 'seed' a university spin-out and build it to attract the attention of high-quality investors. With our sector knowledge, experience with early-stage businesses and local presence in the market, Mercia is ideally placed to work with Invizius, and others like it, to create new Scottish success stories."